BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24865460)

  • 1. mTOR pathway is activated by PKA in adrenocortical cells and participates in vivo to apoptosis resistance in primary pigmented nodular adrenocortical disease (PPNAD).
    de Joussineau C; Sahut-Barnola I; Tissier F; Dumontet T; Drelon C; Batisse-Lignier M; Tauveron I; Pointud JC; Lefrançois-Martinez AM; Stratakis CA; Bertherat J; Val P; Martinez A
    Hum Mol Genet; 2014 Oct; 23(20):5418-28. PubMed ID: 24865460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PKA regulatory subunit 1A inactivating mutation induces serotonin signaling in primary pigmented nodular adrenal disease.
    Bram Z; Louiset E; Ragazzon B; Renouf S; Wils J; Duparc C; Boutelet I; Rizk-Rabin M; Libé R; Young J; Carson D; Vantyghem MC; Szarek E; Martinez A; Stratakis CA; Bertherat J; Lefebvre H
    JCI Insight; 2016 Sep; 1(15):e87958. PubMed ID: 27699247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depletion of type IA regulatory subunit (RIalpha) of protein kinase A (PKA) in mammalian cells and tissues activates mTOR and causes autophagic deficiency.
    Mavrakis M; Lippincott-Schwartz J; Stratakis CA; Bossis I
    Hum Mol Genet; 2006 Oct; 15(19):2962-71. PubMed ID: 16963469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRKAR1A mutations in primary pigmented nodular adrenocortical disease.
    Cazabat L; Ragazzon B; Groussin L; Bertherat J
    Pituitary; 2006; 9(3):211-9. PubMed ID: 17036196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cushing's syndrome and fetal features resurgence in adrenal cortex-specific Prkar1a knockout mice.
    Sahut-Barnola I; de Joussineau C; Val P; Lambert-Langlais S; Damon C; Lefrançois-Martinez AM; Pointud JC; Marceau G; Sapin V; Tissier F; Ragazzon B; Bertherat J; Kirschner LS; Stratakis CA; Martinez A
    PLoS Genet; 2010 Jun; 6(6):e1000980. PubMed ID: 20548949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein kinase A subunit expression is altered in Bloom syndrome fibroblasts and the BLM protein is increased in adrenocortical hyperplasias: inverse findings for BLM and PRKAR1A.
    Heyerdahl SL; Boikos S; Horvath A; Giatzakis C; Bossis I; Stratakis CA
    Horm Metab Res; 2008 Jun; 40(6):391-7. PubMed ID: 18401830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of the Carney complex gene 1 (protein kinase A regulatory subunit 1A) inhibits SMAD3 expression and TGF beta-stimulated apoptosis in adrenocortical cells.
    Ragazzon B; Cazabat L; Rizk-Rabin M; Assie G; Groussin L; Fierrard H; Perlemoine K; Martinez A; Bertherat J
    Cancer Res; 2009 Sep; 69(18):7278-84. PubMed ID: 19738044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of somatic beta-catenin mutations in primary pigmented nodular adrenocortical disease (PPNAD).
    Tadjine M; Lampron A; Ouadi L; Horvath A; Stratakis CA; Bourdeau I
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):367-73. PubMed ID: 18419788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The paradoxical increase in cortisol secretion induced by dexamethasone in primary pigmented nodular adrenocortical disease involves a glucocorticoid receptor-mediated effect of dexamethasone on protein kinase A catalytic subunits.
    Louiset E; Stratakis CA; Perraudin V; Griffin KJ; Libé R; Cabrol S; Fève B; Young J; Groussin L; Bertherat J; Lefebvre H
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2406-13. PubMed ID: 19383776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of steroidogenesis in a primary pigmented nodular adrenocortical disease-associated adenoma leading to virilization and subclinical Cushing's syndrome.
    Hofland J; de Herder WW; Derks L; Hofland LJ; van Koetsveld PM; de Krijger RR; van Nederveen FH; Horvath A; Stratakis CA; de Jong FH; Feelders RA
    Eur J Endocrinol; 2013 Jan; 168(1):67-74. PubMed ID: 23065993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Celecoxib reduces glucocorticoids in vitro and in a mouse model with adrenocortical hyperplasia.
    Liu S; Saloustros E; Berthon A; Starost MF; Sahut-Barnola I; Salpea P; Szarek E; Faucz FR; Martinez A; Stratakis CA
    Endocr Relat Cancer; 2016 Jan; 23(1):15-25. PubMed ID: 26438728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular genetics of primary pigmented nodular adrenocortical disease.
    Sandrini F; Stratakis C
    Arq Bras Endocrinol Metabol; 2004 Oct; 48(5):637-41. PubMed ID: 15761532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-KIT oncogene expression in PRKAR1A-mutant adrenal cortex.
    Nadella K; Faucz FR; Stratakis CA
    Endocr Relat Cancer; 2020 Oct; 27(10):591-599. PubMed ID: 32738126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular cloning, chromosomal localization of human peripheral-type benzodiazepine receptor and PKA regulatory subunit type 1A (PRKAR1A)-associated protein PAP7, and studies in PRKAR1A mutant cells and tissues.
    Liu J; Matyakhina L; Han Z; Sandrini F; Bei T; Stratakis CA; Papadopoulos V
    FASEB J; 2003 Jun; 17(9):1189-91. PubMed ID: 12692076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of the PRKAR1A gene in Cushing's syndrome due to sporadic primary pigmented nodular adrenocortical disease.
    Groussin L; Jullian E; Perlemoine K; Louvel A; Leheup B; Luton JP; Bertagna X; Bertherat J
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4324-9. PubMed ID: 12213893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA signature of primary pigmented nodular adrenocortical disease: clinical correlations and regulation of Wnt signaling.
    Iliopoulos D; Bimpaki EI; Nesterova M; Stratakis CA
    Cancer Res; 2009 Apr; 69(8):3278-82. PubMed ID: 19351815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD.
    Groussin L; Kirschner LS; Vincent-Dejean C; Perlemoine K; Jullian E; Delemer B; Zacharieva S; Pignatelli D; Carney JA; Luton JP; Bertagna X; Stratakis CA; Bertherat J
    Am J Hum Genet; 2002 Dec; 71(6):1433-42. PubMed ID: 12424709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different expression of protein kinase A (PKA) regulatory subunits in cortisol-secreting adrenocortical tumors: relationship with cell proliferation.
    Mantovani G; Lania AG; Bondioni S; Peverelli E; Pedroni C; Ferrero S; Pellegrini C; Vicentini L; Arnaldi G; Bosari S; Beck-Peccoz P; Spada A
    Exp Cell Res; 2008 Jan; 314(1):123-30. PubMed ID: 17904549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary pigmented nodular adrenocortical disease reveals insulin-like growth factor binding protein-2 regulation by protein kinase A.
    Shi Z; Henwood MJ; Bannerman P; Batista D; Horvath A; Guttenberg M; Stratakis CA; Grimberg A
    Growth Horm IGF Res; 2007 Apr; 17(2):113-21. PubMed ID: 17280861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRKAR1A Mutations and protein kinase A interactions with other signaling pathways in the adrenal cortex.
    Robinson-White A; Meoli E; Stergiopoulos S; Horvath A; Boikos S; Bossis I; Stratakis CA
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2380-8. PubMed ID: 16569736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.